학술논문

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma.
Document Type
Article
Source
Frontiers in Oncology; 2023, p1-7, 7p
Subject
NIVOLUMAB
RENAL cell carcinoma
PROTEIN-tyrosine kinase inhibitors
Language
ISSN
2234943X
Abstract
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)